Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.

Abstract

BACKGROUND:

Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome.

OBJECTIVE:

The aim of this study was to review the preclinical and clinical data on fesoterodine.

METHODS:

The study involved a search of the Medline database and the proceedings volumes of urological congresses.

RESULTS/CONCLUSIONS:

Fesoterodine functions as an orally active prodrug that is converted to the active metabolite 5-hydroxymethyltolterodine by non-specific esterases. 5-Hydroxymethyltolterodine is a muscarinic receptor antagonist. Fesoterodine is primarily eliminated as inactive metabolites along with significant renal excretion as the unchanged active metabolite 5-hydroxymethyltolterodine. Fesoterodine is indicated for use at doses of 4 and 8 mg once daily. In clinical studies both doses of fesoterodine were consistently superior to placebo in improving the symptoms of overactive bladder syndrome, with 8 mg/day having significantly greater effects than 4 mg/day.

• Authors: Martin C Michel
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 9 Issue 10 Pg. 1787-96 (Jul 2008) ISSN: 1744-7666 [Electronic] England
• PMID: 18570610 (Publication Type: Journal Article, Review)

Chemical References

• Benzhydryl Compounds
• Muscarinic Antagonists
• fesoterodine

Topics

• Benzhydryl Compounds (pharmacokinetics, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Interactions
• Humans
• Muscarinic Antagonists (pharmacokinetics, pharmacology, therapeutic use)
• Syndrome
• Urinary Bladder, Overactive (drug therapy)